Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced an oversubscribed $183 million Series C financing. The round was co-led by Nextech and EQT Life Sciences…
Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that the first patients have been dosed in the SURPASS study, a pivotal Phase 2/3 clinical trial evaluating…
Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that ELA026 has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation (BTD)…
Electra Therapeutics Announces ELA026 Granted EMA Orphan Drug Designation for the Treatment of Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
SOUTH SAN FRANCISCO, CA, August 4, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Drug…
Electra Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, CA, January 6, 2025 – Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that it will present at the 43rd annual J.P. Morgan Healthcare Conference…
Electra Therapeutics Presents Positive Clinical Results from Completed Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024
SOUTH SAN FRANCISCO, CA, December 9, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced the presentation of positive results from the completed Phase 1b study of ELA026…
Electra Therapeutics to Present Clinical Results for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024
SOUTH SAN FRANCISCO, CA, November 5, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced today that clinical data for its lead drug candidate, ELA026, has been selected…
Electra Therapeutics Receives FDA Fast Track Designation for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
SOUTH SAN FRANCISCO, CA, November 4, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation…
Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
SOUTH SAN FRANCISCO, CA, October 30, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation…
Electra Therapeutics to Present Clinical Data for ELA026 in the Treatment of sHLH in an Oral Session at the 2024 Annual Meeting of the Histiocyte Society
SOUTH SAN FRANCISCO, CA, October 29, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced today that the company will present clinical data for its lead drug candidate, ELA026…
